NovoCure Limited (NASDAQ:NVCR) Q1 2026 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the NovoCure's Q1 2026 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Novocure Ltd (NVCR)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Soleus Capital Guy Levy | 10,492,391 | $114,367,062 | +23% | 4.63% |
| 2. | Quantinno Capital Hoon Kim | 2,487,376 | $27,112,398 | +24% | 0.05% |
| 3. | Renaissance Technologies Jim Simons | 1,551,554 | $16,911,939 | +12% | 0.03% |
| 4. | Point72 Asset Management Steve Cohen | 1,361,391 | $14,839,162 | +52% | 0.02% |
| 5. | Palo Alto Investors William Leland Edwards | 1,280,439 | $13,956,785 | -2% | 2.13% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $12.22 | 81,550 | $996,859.05 | 437,569 | 2025-09-05 | Filing | |
| $11.50 | 5,000 | $57,500.00 | 141,150 | 2025-07-29 | Filing | |
| $11.60 | 5,000 | $58,000.00 | 136,150 | 2025-07-29 | Filing | |
| $11.63 | 10,000 | $116,300.00 | 131,150 | 2025-07-29 | Filing | |
| $96.50 | 104 | $10,036.00 | 13,276 | 2021-11-26 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.93 | 34,273 | $614,634.85 | 459,520 | 2026-06-04 | Filing | |
| $15.77 | 2,945 | $46,444.71 | 89,499 | 2026-06-02 | Filing | |
| $15.77 | 2,945 | $46,444.71 | 11,324 | 2026-06-02 | Filing | |
| $15.77 | 2,945 | $46,444.71 | 11,324 | 2026-06-02 | Filing | |
| $15.77 | 2,945 | $46,444.71 | 14,288 | 2026-06-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 17,069,149 | $186,053,728 | 0.01% | |
| 2. | 13,193,765 | $143,812,040 | 0% | |
| 3. | 6,251,701 | $68,143,541 | 0% | |
| 4. | 4,682,064 | $51,034,498 | 0% | |
| 5. | 4,541,526 | $49,502,634 | 0% |
News See All
NovoCure Limited (NASDAQ:NVCR) Q4 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the NovoCure Fourth Quarter 2025 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded.
NovoCure Limited (NASDAQ:NVCR) Q3 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Novocure Third Quarter 2025 Earnings Call. [Operator Instructions] Please be advised, today's conference is being recorded.
Leerink Partners Reiterates a Buy Rating on NovoCure Limited (NVCR)
NovoCure Limited (NASDAQ:NVCR) is one of the best medical device stocks to buy according to analysts. Leerink Partners analyst Jonathan Chang reiterated a Buy rating on NovoCure Limited (NASDAQ:NVCR) ...
12 Best Medical Device Stocks to Buy According to Analysts
On July 7, CNBC’s Chery Kang and Elaine Yu talked about China’s imposition of reciprocal tariffs on the import of medical devices from the European Union.
NovoCure Limited (NASDAQ:NVCR) Q2 2025 Earnings Call Transcript
Operator: Good day. Thank you for standing by. Welcome to Novocure's Second Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that today's conference may be recorded.
Zai Lab Limited (ZLAB) & NovoCure Limited (NVCR)'s TTFields Therapy Succeeds in Phase 3 Trial
Zai Lab Limited (NASDAQ:ZLAB) and NovoCure Limited (NASDAQ:NVCR) revealed landmark results from the Phase 3 PANOVA-3 trial at the 2025 ASCO Annual Meeting, marking the first therapy to show statistically...
NovoCure Limited (NASDAQ:NVCR) Q1 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the NovoCure Limited First Quarter 2025 Earnings Call. At this time, all participants are in a listen-only mode.
NovoCure Limited (NASDAQ:NVCR) Q4 2024 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the NovoCure Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
8 Stocks on Jim Cramer's Radar
Jim Cramer, host of Mad Money, recently discussed some of the significant challenges the alcohol industry is facing.
Hedge Fund Resource Center